VBR vs. ISCV: Comparing Two Small-Cap Value ETF Heavyweights

The Motley FoolThe Motley Fool
|||6 min read
Key Takeaway

$VBR dominates $ISCV in scale ($62.3B vs $594.6M) with better liquidity, while $ISCV edges performance (18.3% vs 17.9%) with higher yield.

VBR vs. ISCV: Comparing Two Small-Cap Value ETF Heavyweights

VBR vs. ISCV: Comparing Two Small-Cap Value ETF Heavyweights

Vanguard's $VBR and iShares' $ISCV both offer low-cost exposure to U.S. small-cap value stocks, but they differ meaningfully in scale, performance, and liquidity. These two competing products represent the democratization of small-cap value investing, with expense ratios hovering near zero and billions in combined assets. Yet despite their surface similarities, investors choosing between them face a decision that hinges on their priorities around fund size, portfolio volatility, yield generation, and trading efficiency.

The small-cap value segment has become increasingly competitive as asset managers race to capture flows in this historically lucrative corner of the equity market. Both $VBR and $ISCV track distinct methodologies for identifying undervalued stocks in the sub-$3 billion market cap universe, yet their structural differences reveal important trade-offs worth understanding.

Key Differences: Scale, Performance, and Risk Profile

$VBR commands a dominant market position with $62.3 billion in assets under management, dwarfing $ISCV's $594.6 million war chest. This 105-fold size difference carries profound implications for how each fund operates:

While the performance gap appears modest—$ISCV outpaced $VBR by 40 basis points over the trailing year—the volatility metrics tell a different story. $VBR's substantially lower maximum drawdown suggests its larger asset base and more disciplined fund structure have created a smoother investor experience during market dislocations. This matters profoundly for risk-averse allocators who may panic-sell during sharp corrections.

The yield differential between the funds, though narrow, reflects subtle differences in sector weighting and dividend policy selection. $ISCV's 2.0% yield versus $VBR's 1.9% indicates the iShares fund may carry slight overweight exposure to higher-yielding sectors like utilities, real estate, or consumer staples within the small-cap value universe. For income-focused investors, this 10 basis point advantage compounds meaningfully over decades.

Market Context: The Small-Cap Value Landscape

Small-cap value stocks occupy a unique niche within the broader equity ecosystem. These stocks typically trade at significant discounts to their intrinsic value and benefit from substantial operational leverage during economic expansions. Unlike mega-cap technology firms that dominate modern portfolio construction, small-cap value offers exposure to regional banks, industrial manufacturers, specialty retailers, and other sectors deeply tied to Main Street economic activity.

The explosion of passive investing has transformed small-cap value from a specialized quant strategy into a mainstream allocation building block. Institutions and individual investors increasingly recognize that small-cap value's historically superior long-term returns come with greater volatility and less predictable near-term performance than large-cap alternatives.

$VBR's dominant position reflects Vanguard's brand strength and its investor-owned mutual structure, which encourages long-term capital retention. The fund's $62.3 billion scale generates substantial liquidity, tighter bid-ask spreads, and economies of scale that Vanguard passes to shareholders through its already minuscule fee. Competing against $VBR means smaller rivals like $ISCV must excel in other dimensions—whether through superior security selection, better tax efficiency, or differentiated index methodology.

The 5 basis point fee differential between $VBR and $ISCV appears trivial until compounded over a 30-year investment horizon, where it translates into meaningful wealth erosion for large portfolios. For a $500,000 position, that 1 basis point gap costs approximately $50 annually—a rounding error for casual investors but a material expense for professionals managing significant capital.

Investor Implications: Choosing Your Small-Cap Value Vehicle

The decision between $VBR and $ISCV depends less on which fund is "better" and more on which aligns with specific portfolio objectives and constraints.

Choose $VBR if:

  • Liquidity and trading efficiency matter significantly to your strategy
  • You value Vanguard's investor-owned structure and long-term capital retention focus
  • You prefer lower volatility and maximum drawdown during market crashes
  • Your position size is large enough that bid-ask spreads impact returns noticeably
  • You're building a core long-term small-cap value allocation intended to hold for decades

Choose $ISCV if:

  • Maximizing yield is a portfolio priority given your income needs
  • You're willing to tolerate slightly higher drawdowns for modest performance enhancement
  • You prefer iShares' broader product ecosystem and integration capabilities
  • Your position size is modest enough that expense ratios matter more than liquidity
  • You believe the fund's sector weighting better aligns with your economic outlook

From a risk-adjusted perspective, $VBR's lower maximum drawdown represents insurance worth considering. Small-cap value stocks experienced their 2008 financial crisis nadir as investors fled risk assets entirely, with the Russell 2000 Value Index plummeting over 50%. A fund structure demonstrably less volatile during such systemic stress has genuine value, particularly for investors nearing retirement or with reduced psychological tolerance for equity volatility.

The near-identical expense ratios deserve emphasis—both funds operate at a cost structure that would have seemed impossible two decades ago. Competition between Vanguard, BlackRock ($BLK), and other asset managers has compressed fees to levels where active management struggles to justify its costs. This represents an unambiguous victory for long-term investors, who increasingly access sophisticated factor exposures for pennies on the dollar.

Forward-Looking Considerations

Small-cap value's long-term return profile remains compelling, but near-term momentum has shifted. The ongoing dominance of mega-cap technology stocks in equity market returns has created valuations so disparate that value investors face genuine patience tests. Small-cap value may underperform for extended periods during tech booms, only to dramatically outperform during mean reversion episodes.

For investors making this decision, tax efficiency deserves mention. While neither fund publishes specific after-tax return data in the original summary, passive funds like $VBR and $ISCV generally demonstrate superior tax efficiency compared to active small-cap value managers, making them particularly attractive in taxable accounts.

Ultimately, neither fund is demonstrably superior in absolute terms. $VBR's dominant scale, liquidity, and lower drawdown volatility suit most investors, while $ISCV's modest performance edge and higher yield appeal to income-focused or performance-chasing allocators. The meaningful choice involves deciding whether small-cap value belongs in your portfolio at all—a far more consequential question than selecting between two competitively priced vehicles offering nearly identical exposure.

Source: The Motley Fool

Back to newsPublished Mar 17

Related Coverage

The Motley Fool

Energy Dividends Face Off: Why ConocoPhillips Edges EOG Resources

ConocoPhillips and EOG Resources both offer dividend yields above 2.5%, but ConocoPhillips' aggressive growth plans and free cash flow projections make it the stronger choice for income investors.

EOGCOP
The Motley Fool

Healthcare's Dividend Gems: Why $ABBV and $BMY Stand Out for Income Investors

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

BMYCELGrABBV
The Motley Fool

BMY's 4.4% Dividend Masks Looming Patent Cliff Risks

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

BMYCELGr
The Motley Fool

Energy Stocks Surge as Geopolitical Tensions Push Oil Above $100

Oil prices above $100 spark renewed interest in energy stocks. ExxonMobil, Schlumberger, and Enterprise Products Partners emerge as compelling opportunities amid geopolitical tensions.

XOMEPDSLB
The Motley Fool

AbbVie Stock Trades at Bargain Valuation as New Drugs Offset Humira Decline

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

ABBVXLV
The Motley Fool

Two Dividend Powerhouses for Long-Term Wealth Building

$PINE and $HD offer distinct dividend strategies for long-term investors: Alpine Income provides 6.34% yield with REIT protections; Home Depot delivers growth plus 2.88% yield.

HDPINEPINEpA